Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This item is described as 'multivalent pneumococcal conjugate formulation 2', identified as the freeze-dried powder component of a two-part ('1+1' combination mode) pneumococcal conjugate vaccine system. It contains pneumococcal conjugates prepared from serotypes 8, 10A, 11A, 15B, 22F, 24F, 33F, and 35B, utilizing tetanus toxoid as carrier proteins. This formulation is designed to either supplement existing pneumococcal conjugate vaccines (like 10-valent or 13-valent ones) to broaden coverage or combine with a liquid component (containing 15 serotypes) to create a broader-spectrum vaccine (potentially covering 23 serotypes in total).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Multivalent pneumococcal conjugate formulation 2.